Advances at Mass General Cancer Center

Drs. Shannon Stott and Brian Nahed explain why their new technology is an important breakthrough for glioblastoma patients, and share what’s next for their research.

Drs. Shannon Stott and Brian Nahed describe a new technique that uses microfluidics and engineered nanosurfaces to capture EVs released from glioblastoma multiforme, the most common and aggressive form of brain cancer.

In this episode, Drs. Shannon Stott and Brian Nahed explain their backgrounds and share how they met and began working with each other.

In this episode, Ethel Pereira and Tim Padera share why the protocol in this study isn’t safe to use for humans yet, and what the next steps will advance the research to improve patient care.

Tim Padera, PhD, and research fellow, Ethel Pereira, PhD, provide insight into their study of transit tumor cells.

Listen to hear how Tim Padera made his way from being an engineer in Chicago to becoming a cancer researcher in Boston.

In this episode we’ll hear about Ethel Pereira’s background and how she became interested in science, and specifically in cancer research.

Dr. David Miyamoto explains the impact of his research in prostate cancer, and mentions how it can potentially translate to bladder cancer.

Dr. David Miyamoto explains his study that examines new technology for treating prostate cancer.

In this episode, Dr. David Miyamoto shares how his parents met and explains the journey of how he ended up at the Mass General Cancer Center.

Dr. Ryan Corcoran talks about where his research is going and why it is so important to understanding divergent resistance mechanisms.

Listen to Dr. Ryan Corcoran as he explains two of his studies, the first is about a way to treat a range of resistance strategies within BRAF mutations, and the second is about a novel pooled clone system that allows for monitoring the evolution of heterogeneous tumors as they happen.

In this episode, we’ll hear about Dr. Ryan Corcoran’s personal journey and how he came to the Mass General Cancer Center after growing up in California.

Dr. Lee Zou explains why understanding ATR inhibition in tumor cells is important, and shares what’s next for him and his team.

Listen to learn about the discovery Dr. Lee Zou and his team made regarding mitosis and ATR inhibition in tumor cells.

In this episode, we learn about Dr. Lee Zou’s childhood in China and how his parents impacted his decision to make a career out of science.

Dr. Miguel Rivera explains the future of Ewing Sarcoma and shares the importance of finding ways to make reactions between proteins more efficient inside the cell.

Listen to Dr. Miguel Rivera who explains why prion-like domains in mutant EWS-Fli-1 fusion proteins are instrumental in activating Ewing Sarcoma oncogenes.

In this episode, we’ll hear about Miguel’s background, his interest in science and medicine, and what path he’s taken to get to where he is today.

Dr. Nir Hacohen explains where he sees cancer immunotherapy research and therapies going in the future, and what he thinks is next for his team and his lab.

Learn about how Dr. Nir Hacohen’s lab works to understand mechanism underline resistance to immune check point blockade therapy in metastatic melanoma and how his lab is setting the ground work for two potential new therapies.

Listen to Dr. Nir Hacohen as he remembers his recruitment to the Mass General Hospital and what brought him to join the Mass General Cancer Center.

Dr. Priscilla Brastianos gives a detailed account of the clinical trials that she has opened at the Mass General Cancer Center.

Listen to Dr. Priscilla Brastianos as she explains her studies on new genetic-based treatment for glioneuronal tumors and glioblastoma.

Learn more about Dr. Priscilla Brastianos’ interesting background including her Greek and Canadian upbringing, why she became an oncologist, and what drives her every day to make advances in cancer treatments.

Hear what Dr. Othon Iliopoulos has planned in regards to combination therapy for renal cell carcinoma, as well as his medical efforts in Greece.

Dr. Othon Iliopoulos explains his team’s recent findings on combination therapy for renal cell carcinoma and explains the clinical relevance to this discovery.

Listen to learn about Dr. Othon Iliopoulos’ interesting background, including his passion for social activism, and his efforts to build a science community in Greece.

Listen to find out how Lipika Goyal, MD, will be continuing her research, what drugs are on the horizon, and what’s next for her.

Listen to Dr. Lipika Goyal discuss her research of the genetic mechanisms that drive resistance and that may lead to better therapies for bile duct and other cancers.

Listen to learn about Dr. Lipika Goyal’s educational and personal background and why she chose the path that she did.

Hear more about what’s next for this line of work, and about where Dr. Mario Suvà sees things going in this field of research.

Learn more about Dr. Mario Suvà’s work on single-cell RNA sequencing of IDH-mutant glioma samples and how identifying cell lineages, phenotypes, and microenvironments may lead to new therapies.

Learn about Dr. Mario Suvà’s educational and personal background and what sparked his interest in medicine and science.

Listen to find out about the future direction of Nabeel Bardeesy’s research, and the exciting application of his team’s findings to launch a new clinical trial.

Hear more from Nabeel Bardeesy about the discovery of a novel epigenetic-metabolic pathway that suggest therapeutic targets in tumors with combined KRAS and LKB1 mutations.

Learn more about his background and how he became interested in science.

In this episode, Drs. Aditya Bardia and Shyamala Maheswaran explain the next steps in their study and what it will take to keep advancing their research of HER2 cells.

In this episode, we talk with Drs. Aditya Bardia and Shyamala Maheswaran about their recently published study showing that breast cancer cells can spontaneously switch from a HER2-positive to a HER2-negative state and vice versa, and that this understanding can help lead to novel targeted treatments.

In this episode, Drs. Aditya Bardia and Shyamala Maheswaran discuss their unique backgrounds, including why they came to the United States and what led them to where they are today.

In this episode, Areej El-Jawahri, MD, discusses the future of palliative care for curative intent, her plans to continue with a replication study, and what’s required to move things forward.

In this episode, Areej El-Jawahri explains hematopoietic stem cell transplantation and her study showing why palliative care can be beneficial to patients and their family members.

In this episode, Areej El-Jawahri, MD, discusses her personal background and her career path, both of which have conventional and unique characteristics.

Nir Hacohen, PhD, talks more about immunology and how it may impact the future of cancer care.

Nir Hacohen, PhD, walks us through his recent research findings and helps us understand how these and related discoveries have already paved the way to novel cancer treatments.

Nir Hacohen, PhD, talks about how he got started in science and immunology. We also find out what drives him day in and day out.

Raul Mostoslavsky, MD, PhD, discusses where he sees the field of epigenetic research going in the future.

Raul Mostoslavsky, MD, PhD, digs deeper into his recent publication on new therapeutic targets for pancreatic cancer.

Raul Mostoslavsky, MD, PhD, discusses his journey, his culture, and what led him to pursue research.